Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG

Biotech Giants' Cost Efficiency: A Decade in Review

__timestampMorphoSys AGRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 201477000205018000
Thursday, January 1, 201577000392709000
Friday, January 1, 201697000299694000
Sunday, January 1, 201733000397061000
Monday, January 1, 20181796629434100000
Tuesday, January 1, 201912085198782200000
Wednesday, January 1, 202091741461119900000
Friday, January 1, 2021322000002437500000
Saturday, January 1, 2022486200001560400000
Sunday, January 1, 2023583550001815800000
Monday, January 1, 20241970500000
Loading chart...

Unleashing insights

A Tale of Two Biotechs: Cost Efficiency in Focus

In the competitive world of biotechnology, cost efficiency is a critical factor for success. Regeneron Pharmaceuticals, Inc. and MorphoSys AG, two giants in the industry, have shown contrasting trends in their cost of revenue from 2014 to 2023.

Regeneron, a leader in the field, has consistently maintained a higher cost of revenue, peaking at approximately $1.8 billion in 2023. This represents a staggering 785% increase from 2014. In contrast, MorphoSys AG, while starting with a modest cost of revenue, has seen a dramatic rise, reaching around $58 million in 2023, marking an exponential growth of over 75,000% since 2014.

These figures highlight the differing strategies and market positions of these companies. While Regeneron’s substantial costs reflect its expansive operations, MorphoSys’s rapid growth indicates its aggressive expansion in recent years.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025